Skip to content

Metacognition Assessment in Patient With Multiple Sclerosis

Metacognition Assessment in Patient With Multiple Sclerosis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04240379
Acronym
METACOGSEP
Enrollment
80
Registered
2020-01-27
Start date
2020-06-11
Completion date
2022-04-08
Last updated
2022-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Multiple Sclerosis, Multiple Sclerosis Functional Composite (MSFC), Metacognition

Brief summary

This study will assessed the level of consciousness of MS patients suffering of cognitive and motor disorders. Understanding the awareness of the disease is crucial to allow better management of these patients. It has been shown, for other neurological pathologies, that a lack of awareness of deficits leads to inefficient rehabilitation and a disorder of understanding the impact of deficits in daily activities. Metacognition could be altered with age, so we will include participants between 18 and 60 years old.

Detailed description

Subject who have to do neurological assessement by the Multiple sclerosis Functional Composite (MSFC) will be enrolled. The patient will estimate the time to undergo the test. This time will be compared to the time really make by the patient to realise test.

Interventions

None listed

Sponsors

University Grenoble Alps
CollaboratorOTHER
University Hospital, Grenoble
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of multiple sclerosis * Voluntary for participate to study

Exclusion criteria

* Neurological disease other than Multiple Sclerosis * psychiatric disease, other than depressiveness * illicit substance abuse * Persons referred to in Articles L1121-5 to 8 of the French Public Health Code

Design outcomes

Primary

MeasureTime frameDescription
Metacognitive precisionDay 1Metacognitive precision based on Multiple Sclerosis Functional Composite (MSFC) score

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026